The story of how international pharmaceutical company Grindex automated safety case detection and scaled its PV program with DrugCard.
The Challenge: Manual Workload, Missed Insights, and Growing Global Demands
Operating across 23 countries with 835 products, Grindex’s pharmacovigilance team faced an unsustainable challenge. Their PV specialists were overwhelmed by time-consuming manual processes that limited both efficiency and compliance.
Before adopting DrugCard, Grindex struggled with:
- 2,864 local literature articles requiring manual screening, each taking ~25 minutes.
- Difficulty identifying safety-relevant articles and reportable cases across multilingual sources.
- Increasing regulatory obligations in emerging and established markets.
- The need for consistent, traceable PV workflows across all 23 regions.
Scaling pharmacovigilance operations under these conditions had become a serious operational and compliance risk.
The Solution: AI-Driven Literature Monitoring and ICSR Detection with DrugCard
To overcome these challenges, Grindex deployed DrugCard, an AI-powered platform purpose-built for automated global and local literature monitoring.
By integrating DrugCard into their workflow, the team gained:
- AI-enhanced screening and categorisation for all literature sources.
- PV relevance detection and automatic ICSR identification for faster safety signal capture.
- Seamless PubMed integration for comprehensive global coverage.
- Access to 89+ countries, supporting smooth market expansion and regulatory readiness.
- Quality control reports ensured ongoing data integrity and full audit traceability.
Previously, the process required hours of manual review. However, it has since become streamlined and auditable. As a result, Grindex’s small PV team can manage a growing global footprint with confidence.
The Results: Global Scalability and Regulatory Confidence
DrugCard delivered measurable impact across efficiency, compliance, and scalability:
- 88% reduction in screening time – from 25 minutes to ~3 minutes per article.
- 2,864 articles reviewed efficiently by just 3 PV specialists in 4 months.
- 25 safety-relevant articles identified, including 13 reportable safety cases.
- Expanded pharmacovigilance coverage across 23 countries.
- Zero missed cases and consistent audit readiness through automated QC reporting.
By implementing DrugCard, Grindex successfully transformed its PV operations into a scalable, AI-driven system. Consequently, it now detects risks early and ensures full compliance across global markets.
Ready to Achieve Similar Results?
Stop wasting valuable PV resources on manual screening.
Let DrugCard automate your literature monitoring, streamline safety case detection, and help your team stay fully compliant across every market.
